924202
5-Amino-Thalidomide
≥95%
동의어(들):
5-Amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione, C5 Pomalidomide, PROTAC® research ligand
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C13H11N3O4
CAS 번호:
Molecular Weight:
273.24
UNSPSC Code:
12352101
NACRES:
NA.22
MDL number:
ligand
thalidomide
Quality Level
assay
≥95%
form
powder
SMILES string
O=C1C2=CC=C(N)C=C2C(=O)N1C3C(=O)NC(=O)CC3
InChI
1S/C13H11N3O4/c14-6-1-2-7-8(5-6)13(20)16(12(7)19)9-3-4-10(17)15-11(9)18/h1-2,5,9H,3-4,14H2,(H,15,17,18)
InChI key
IICWMVJMJVXCLY-UHFFFAOYSA-N
Application
5-Amino-Thalidomide is a derivative of the Cereblon (CRBN)-binding ligand thalidomide. 5-Amino-Thalidomide can be used to bind the CRBN E3 ubiquitin ligase in targeted protein degradation research or in the synthesis
of protein degraders with a C5 exit vector. This was previously listed under AMBH2D6FF88F.
Related Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation
Browse our growing synthesis and research tools: Protein Degrader Building Blocks
of protein degraders with a C5 exit vector. This was previously listed under AMBH2D6FF88F.
Related Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation
Browse our growing synthesis and research tools: Protein Degrader Building Blocks
Other Notes
Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1
Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton′s Tyrosine Kinase Using PROTAC-Mediated Degradation
Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton′s Tyrosine Kinase Using PROTAC-Mediated Degradation
Legal Information
PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Acute Tox. 4 Dermal - Repr. 1A
저장 등급
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Alexandru D Buhimschi et al.
Biochemistry, 57(26), 3564-3575 (2018-06-01)
Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies, yet >80% of CLL patients develop resistance due to a cysteine
국제 무역 품목 번호
| SKU | GTIN |
|---|---|
| 924202-100MG | 04065267248943 |
| 924202-250MG | 04065267248950 |